Literature DB >> 24825777

Regulation of T cell responses by the receptor molecule Tim-3.

Jacob V Gorman1, John D Colgan.   

Abstract

Tim-3 is a member of the T cell immunoglobulin and mucin domain (Tim) family of proteins, which are expressed by several cell types in the immune system, including CD4 and CD8 T cells activated under certain conditions. These molecules are generally thought to act as receptors for multiple ligands and thus to function by engaging intracellular signaling pathways in a ligand-dependent manner. In recent years, the function of the Tim-3 protein has been studied in some detail, particularly with respect to its role in the regulation of CD4 and CD8 T cell responses. Here, we review the structural features of Tim-3, known ligands for this molecule and the links established between Tim-3 and signal transduction pathways. In addition, we review the current literature regarding the role of Tim-3 in the regulation of effector responses by CD4 and CD8 T cells. Overall, findings published thus far strongly support the conclusion that Tim-3 functions to inhibit T cell responses, particularly under conditions involving chronic stimulation. Conversely, some reports have provided evidence that Tim-3 can stimulate T cells under conditions involving acute stimulation, suggesting that the role of Tim-3 may vary depending on context. Further study of Tim-3 is likely to advance our understanding of how CD4 and CD8 T cell responses are regulated and could uncover novel approaches for manipulating T cell function for therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24825777      PMCID: PMC4125508          DOI: 10.1007/s12026-014-8524-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  104 in total

1.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

2.  Tim3 is upregulated and protective in nephrotoxic serum nephritis.

Authors:  Andrea Schroll; Kathrin Eller; Julia M Huber; Igor M Theurl; Anna M Wolf; Günter Weiss; Alexander R Rosenkranz
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

3.  T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase.

Authors:  Anjali J de Souza; Jean S Oak; Ryan Jordanhazy; Rosemarie H DeKruyff; David A Fruman; Lawrence P Kane
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

Review 4.  The costimulatory role of TIM molecules.

Authors:  Roselynn Rodriguez-Manzanet; Rosemarie DeKruyff; Vijay K Kuchroo; Dale T Umetsu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.

Authors:  Masafumi Nakayama; Hisaya Akiba; Kazuyoshi Takeda; Yuko Kojima; Masaaki Hashiguchi; Miyuki Azuma; Hideo Yagita; Ko Okumura
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

6.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

7.  Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis.

Authors:  Fengmin Shi; Xiaoqin Guo; Xingwei Jiang; Ping Zhou; Yan Xiao; Tingting Zhou; Guojiang Chen; Zhi Zhao; He Xiao; Chunmei Hou; Xinying Li; Xiaomei Yang; Renxi Wang; Jiannan Feng; Beifen Shen; Yan Li; Gencheng Han
Journal:  Clin Immunol       Date:  2012-09-18       Impact factor: 3.969

8.  Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation.

Authors:  Haruna Niwa; Takahiro Satoh; Yuki Matsushima; Kazuki Hosoya; Kazumi Saeki; Toshiro Niki; Mitsuomi Hirashima; Hiroo Yokozeki
Journal:  Clin Immunol       Date:  2009-05-23       Impact factor: 3.969

9.  Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Authors:  Lukas Baitsch; Amandine Legat; Leticia Barba; Silvia A Fuertes Marraco; Jean-Paul Rivals; Petra Baumgaertner; Céline Christiansen-Jucht; Hanifa Bouzourene; Donata Rimoldi; Hanspeter Pircher; Nathalie Rufer; Maurice Matter; Olivier Michielin; Daniel E Speiser
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

10.  TIM-3 does not act as a receptor for galectin-9.

Authors:  Judith Leitner; Armin Rieger; Winfried F Pickl; Gerhard Zlabinger; Katharina Grabmeier-Pfistershammer; Peter Steinberger
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

View more
  25 in total

1.  Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function.

Authors:  Jacob V Gorman; John D Colgan
Journal:  Immunology       Date:  2018-02-08       Impact factor: 7.397

2.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Authors:  Gulidanna Shayan; Raghvendra Srivastava; Jing Li; Nicole Schmitt; Lawrence P Kane; Robert L Ferris
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

3.  Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

Authors:  Lyndsay Avery; Jessica Filderman; Andrea L Szymczak-Workman; Lawrence P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

4.  Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells.

Authors:  Miriam Victoria Martín-Manzo; Carlos Lara; Cruz Vargas-de-Leon; Julio Carrero; Gloria Queipo; Miguel Fonseca-Sanchez; Nancy R Mejia-Dominguez; David Kershenobich; Srinivas Mummidi; Alejandro Zentella-Dehesa; Joselin Hernandez
Journal:  Pathol Oncol Res       Date:  2019-02-13       Impact factor: 3.201

Review 5.  Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.

Authors:  Hanna A Knaus; Christopher G Kanakry; Leo Luznik; Ivana Gojo
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 6.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

7.  Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.

Authors:  Jacob K Files; Sushma Boppana; Mildred D Perez; Sanghita Sarkar; Kelsey E Lowman; Kai Qin; Sarah Sterrett; Eric Carlin; Anju Bansal; Steffanie Sabbaj; Dustin M Long; Olaf Kutsch; James Kobie; Paul A Goepfert; Nathan Erdmann
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

8.  TIM-3 Rs10515746 (A/C) and Rs10053538 (C/A) Gene Polymorphisms and Risk of Multiple Sclerosis.

Authors:  Esmat Yaghoobi; Saeed Abedian; Omid Babani; Maryam Izad
Journal:  Iran J Public Health       Date:  2016-05       Impact factor: 1.429

Review 9.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

10.  Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation.

Authors:  Binh L Phong; Lyndsay Avery; Tina L Sumpter; Jacob V Gorman; Simon C Watkins; John D Colgan; Lawrence P Kane
Journal:  J Exp Med       Date:  2015-11-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.